Nanobiotix modifies the protocol of its phase 3 cancer study

On May 4, 2026, Nanobiotix announced that the FDA had accepted an amendment to the protocol for the NANORAY-312 study. This change, initiated by Johnson & Johnson, eliminates the interim analysis and modifies the final analysis to include fewer events. This could expedite the registration of JNJ-1900 (NBTXR3) for head and neck cancers.

Nanobiotix anticipates that the new final analysis will be completed within the same timeframe as the planned interim analysis. The company is also eligible to receive significant payments related to the progress of the first two programs involving JNJ-1900 (NBTXR3).